73 related articles for article (PubMed ID: 27354598)
1. Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Schmidt-Wolf IG
Anticancer Res; 2016 Jul; 36(7):3395-400. PubMed ID: 27354598
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Blaum-Feder S; Schmidt-Wolf IG
Anticancer Res; 2015 Nov; 35(11):5921-6. PubMed ID: 26504016
[TBL] [Abstract][Full Text] [Related]
3.
Schmeel LC; Schmeel FC; Schmidt-Wolf IGH
Anticancer Res; 2017 Jul; 37(7):3513-3520. PubMed ID: 28668840
[TBL] [Abstract][Full Text] [Related]
4. Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Mar; 35(3):1369-76. PubMed ID: 25750287
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Endo T; Schmidt-Wolf IG
Anticancer Res; 2015 Feb; 35(2):835-41. PubMed ID: 25667464
[TBL] [Abstract][Full Text] [Related]
6. Griseofulvin Efficiently Induces Apoptosis in
Schmeel LC; Schmeel FC; Kim Y; Blaum-Feder S; Schmidt-Wolf IGH
Anticancer Res; 2017 May; 37(5):2289-2295. PubMed ID: 28476794
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
8. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
9. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
10. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
Schmeel FC; Schmeel LC; Kim Y; Schmidt-Wolf IG
Hematol Oncol; 2014 Dec; 32(4):197-204. PubMed ID: 24470348
[TBL] [Abstract][Full Text] [Related]
11. [The effect of peroxisome proliferator-activated receptor alpha and gamma ligands on free fatty acid-induced INS-1 cell impairment].
Yang LY; Yang YN; Chen ZJ
Zhonghua Nei Ke Za Zhi; 2003 Dec; 42(12):847-50. PubMed ID: 14728875
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anticancer efficacy of snake venom combined with silica nanoparticles in a murine model of human multiple myeloma: molecular targets for cell cycle arrest and apoptosis induction.
Al-Sadoon MK; Rabah DM; Badr G
Cell Immunol; 2013; 284(1-2):129-38. PubMed ID: 23973876
[TBL] [Abstract][Full Text] [Related]
14. Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.
Holien T; Olsen OE; Misund K; Hella H; Waage A; Rø TB; Sundan A
Eur J Haematol; 2013 Oct; 91(4):339-46. PubMed ID: 23869695
[TBL] [Abstract][Full Text] [Related]
15. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
Akbiyik F; Cinar K; Demirpence E; Ozsullu T; Tunca R; Haziroglu R; Yurdaydin C; Uzunalimoglu O; Bozkaya H
Eur J Clin Invest; 2004 Jun; 34(6):429-35. PubMed ID: 15200495
[TBL] [Abstract][Full Text] [Related]
16. The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.
Coleman EJ; Brooks KJ; Smallshaw JE; Vitetta ES
J Immunother; 2006; 29(5):489-98. PubMed ID: 16971805
[TBL] [Abstract][Full Text] [Related]
17. Molecular cloning and regulation of expression of two novel mouse CYP4F genes: expression in peroxisome proliferator-activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges.
Cui X; Kawashima H; Barclay TB; Peters JM; Gonzalez FJ; Morgan ET; Strobel HW
J Pharmacol Exp Ther; 2001 Feb; 296(2):542-50. PubMed ID: 11160642
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
19. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
20. Calmodulin antagonists induce cell cycle arrest and apoptosis in vitro and inhibit tumor growth in vivo in human multiple myeloma.
Yokokura S; Yurimoto S; Matsuoka A; Imataki O; Dobashi H; Bandoh S; Matsunaga T
BMC Cancer; 2014 Nov; 14():882. PubMed ID: 25424011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
